This well-validated score is an excellent clinical tool to assess the risk of intravenous tPA-related symptomatic ICH in patients treated with tPA within 3 h of stroke onset, but it cannot provide an indication on how much benefit patients would gain from this strategy. The gene discussed is PLAT; the disease is Stroke.